Central Venous Access Devices in Oncology: A Comprehensive Clinical Guideline

Evidence-based guideline for selection, insertion, maintenance, and complication management of central venous access devices in oncology patients, synthesized from multiple professional society recommendations.

Records
5
Last revised
March 2026
Editorial responsibility
The Clinical Database

Central venous access devices (CVADs) are fundamental to the delivery of systemic anticancer therapy. The majority of patients with cancer require reliable, durable venous access for chemotherapy, immunotherapy, targeted agents, supportive medications, blood product transfusion, parenteral nutrition, and serial blood sampling. The selection, placement, maintenance, and complication management of these devices directly influence treatment outcomes, patient safety, and quality of life throughout the cancer journey.

This guideline synthesizes recommendations from multiple authoritative professional societies, expert panels, consensus groups, and infusion therapy standards bodies into a single, comprehensive clinical reference. It is intended for oncologists, interventional radiologists, vascular access specialists, infusion nurses, oncology nurses, and all clinicians involved in the care of cancer patients with central venous access devices. Recommendations reflect the current evidence base through early 2026 and incorporate guidance from major oncology professional societies, vascular access organizations, infusion therapy standards bodies, and infection prevention expert panels.12345

The guideline covers the full lifecycle of CVADs in oncology — from initial patient assessment and device selection through insertion, daily maintenance, complication prevention and management, and eventual device removal. Special attention is given to the unique challenges posed by the oncology population, including immunosuppression, thrombocytopenia, prior vessel damage from chemotherapy and radiation, cancer-associated hypercoagulability, and the need for long-term reliable access across multiple lines of therapy.

Contents:

PartTitleCoverage
Part 1Device Selection and Patient AssessmentCVAD types and oncology-specific indications, patient assessment framework, vein selection in cancer patients, device selection algorithms, and special population considerations
Part 2Insertion Techniques and Site CareInsertion site selection, ultrasound-guided placement, tip confirmation, skin antisepsis, dressing and securement, and site care protocols for oncology patients
Part 3Catheter Maintenance ProtocolsFlushing and locking protocols, dressing change procedures, needleless connector management, port access and deaccess procedures, blood sampling, and patency assessment
Part 4Complication Prevention and ManagementCLABSI prevention and treatment, catheter-associated thrombosis, occlusion management, extravasation, catheter malposition, pinch-off syndrome, and catheter damage
Part 5Special Populations, Device Removal, Patient Education, and Quality MetricsPediatric oncology, elderly patients, thrombocytopenic and anticoagulated patients, device removal criteria and procedures, patient and caregiver education, and quality surveillance

  1. Schiffer CA, Mangu PB, Wade JC, et al. “Central venous catheter care for the patient with cancer: American Society of Clinical Oncology clinical practice guideline.” J Clin Oncol, 31(10), 1357-1370, 2013. American Society of Clinical Oncology (ASCO). doi:10.1200/JCO.2012.45.5733. Updated 2022. ↩︎

  2. Gorski LA, Hadaway L, Hagle ME, et al. “Infusion therapy standards of practice.” J Infus Nurs, 44(1S), S1-S224, 2021. Infusion Nurses Society (INS). doi:10.1097/NAN.0000000000000396. ↩︎

  3. Camp-Sorrell D, Matey L, eds. Access Device Standards of Practice for Oncology Nursing. Oncology Nursing Society (ONS); 2017. ↩︎

  4. Defined through the Association for Vascular Access (AVA) Adult Clinical Practice Guidelines published in Journal of the Association for Vascular Access (JAVA), Volume 31, January Supplement, 2026. ↩︎

  5. Defined through the European Society for Medical Oncology (ESMO) consensus recommendations on vascular access in oncology and the International Thrombosis and Cancer Guidelines (ITAC) 2019 clinical practice guidelines for treatment and prophylaxis of venous thromboembolism in patients with cancer. ↩︎

Frequently asked questions

Which central venous access device is best for chemotherapy?
Device selection follows the principle of minimal intervention — the least invasive device with the smallest diameter and fewest lumens that safely completes the prescribed therapy — balanced against treatment duration, vesicant administration, and infection and thrombosis risk. In the CAVA randomised trial comparing PICCs, implanted ports, and tunneled Hickman catheters for systemic anticancer therapy, ports had the lowest overall complication rate and lowest catheter-related bloodstream infection rate, while PICCs had the highest deep vein thrombosis rate. CAVA also found ports cost-effective when the expected duration of use exceeded approximately 3 months.
How often should an implanted port be flushed when not in use?
Ports not in active treatment are flushed every 4-12 weeks with 10 mL of 0.9% sodium chloride followed by 3-5 mL of heparin 100 units/mL, and evidence supports extending the maintenance interval to every 3 months. A minimum 10 mL syringe barrel size should be used for all CVAD flushing, because smaller syringes generate intraluminal pressures that may exceed the catheter’s burst pressure. The pulsatile push-pause technique clears protein and medication residue more effectively than a continuous flush.
How is catheter-associated thrombosis treated in cancer patients?
Per the 2019 ITAC international guidelines, low-molecular-weight heparin or direct oral anticoagulants are the agents of choice for catheter-associated deep vein thrombosis in cancer patients, given for a minimum of 3 months and continued for the duration of catheter dwell if the CVAD is retained. Symptomatic catheter-associated thrombosis occurs in roughly 2-15% of implanted ports and 5-30% of PICCs in cancer populations.

Part 5: Special Populations, Device Removal, Patient Education, and Quality Metrics — Central Venous Access in Cancer Patients

Pediatric oncology, elderly patients, thrombocytopenic and anticoagulated patients, device removal criteria and procedures, patient and caregiver education, and quality surveillance for CVADs in oncology.

guidelines•Mar 2026•guidelines

Part 4: Complication Prevention and Management — Central Venous Access in Cancer Patients

CLABSI prevention and treatment, catheter-associated thrombosis, occlusion management, extravasation, catheter malposition, pinch-off syndrome, and catheter damage in oncology CVAD patients.

guidelines•Mar 2026•guidelines

Part 3: Catheter Maintenance Protocols — Central Venous Access in Cancer Patients

Flushing and locking protocols, dressing change procedures, needleless connector management, port access and deaccess procedures, blood sampling, and patency assessment for CVADs in oncology patients.

guidelines•Mar 2026•guidelines

Part 2: Insertion Techniques and Site Care — Central Venous Access in Cancer Patients

Insertion site selection, ultrasound-guided placement, tip confirmation, skin antisepsis, dressing and securement, and site care protocols for central venous access devices in oncology patients.

guidelines•Mar 2026•guidelines

Part 1: Device Selection and Patient Assessment — Central Venous Access in Cancer Patients

CVAD types and oncology-specific indications, patient assessment framework, vein selection in cancer patients, device selection algorithms, and special population considerations for central venous access in oncology.

guidelines•Mar 2026•guidelines